Study on the treatment of autism spectrum disorders in children with mTOR inhibitor rapamycin

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032184

Enrollment

Unknown

Registered

2020-04-22

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

experimental group:Rapamycin

Eligibility

Sex/Gender

All

Age

1 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. 10 children with autism spectrum disorder (ASD) are selected; 2. Patients aged 1-6 years, male and female unlimited; 3. Evaluation criteria for autism spectrum disorders: the history and behavior observation results can be clinically diagnosed as ASD patients according to the diagnostic criteria in the fifth edition of diagnostic and Statistical Manual of mental disorders (DSM-V).

Exclusion criteria

Exclusion criteria: 1. Children with abnormal liver and kidney functions; 2. Children with immune system disorders; 3. The researcher thinks that it is not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
Score of Autism behavior scale;Gesell scale score;	—

Countries

China

Contacts

Public ContactYang Guang

The First Medical Center of PLA General Hospital

yangg301@sina.com+86 13810192267

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026